考察空腹条件下，健康受试者单次口服由安徽四环科宝制药有限公司提供的奥美拉唑碳酸氢钠干混悬剂（受试制剂T，规格：每袋含奥美拉唑40mg和碳酸氢钠1680mg）或由Salix Pharmaceuticals Inc持证的奥美拉唑碳酸氢钠干混悬剂（参比制剂R，商品名：ZEGERID®，规格：每袋含奥美拉唑40mg和碳酸氢钠1680mg）的药动学特征，评价两制剂间的生物等效性及安全性，为受试制剂的注册申请提供依据。

开始日期2024-06-21

申办/合作机构

安徽四环科宝制药有限公司

CTR20231671 / CompletedN/A

奥美拉唑碳酸氢钠胶囊随机、开放、单剂量、两制剂、交叉设计在中国健康受试者中的生物等效性正式试验

主要研究目的：以宁波美诺华天康药业有限公司的奥美拉唑碳酸氢钠胶囊为受试制剂，并以Salix Pharmaceuticals Inc的奥美拉唑碳酸氢钠胶囊为参比制剂，进行人体生物等效性评价。

开始日期2023-06-12

申办/合作机构

宁波美诺华天康药业有限公司

CTR20231814 / CompletedN/A

随机、开放、单剂量、两制剂、两序列、两周期、自身交叉对照设计，评价中国健康受试者在空腹状态下单次口服奥美拉唑碳酸氢钠胶囊后的生物等效性正式试验

主要目的：以海南广升誉制药有限公司提供的奥美拉唑碳酸氢钠胶囊为受试制剂；并以Salix Pharmaceuticals Inc持证的奥美拉唑碳酸氢钠胶囊为参比制剂，进行人体相对生物利用度和生物等效性评价。

开始日期2023-06-11

申办/合作机构

海南广升誉制药有限公司

100 项与良性胃溃疡相关的临床结果

登录后查看更多信息

100 项与良性胃溃疡相关的转化医学

登录后查看更多信息

0 项与良性胃溃疡相关的专利（医药）

登录后查看更多信息

890

项与良性胃溃疡相关的文献（医药）

2025-01-01·Gene

Host repair polymorphisms and H. pylori genes in gastric disease outcomes: Who are the guardian and villains?

Article

作者: Paulo Por Deus Gomes, João ; Helena Barem Rabenhorst, Silvia ; Maria de Oliveira Barboza, Morgana ; Goberlânio de Barros Silva, Paulo ; Mário Rodríguez Burbano, Rommel ; Ferreira da Costa, Reginaldo

Gastric cancer (GC) is the fourth-leading cause of cancer-related mortality. The intestinal subtype of GC comes after the cascade of Correa, presenting H. pylori infection as the major etiological factor. One of the main mechanisms proposed for the progression from a more benign gastric lesion to cancer is DNA damage caused by chronic inflammation. Polymorphisms in DNA repair genes can lead to an imbalance of host DNA damage and repair, contributing to the development of GC. From there, we evaluated the risk of polymorphisms in DNA repair system genes in progressive gastric diseases and their association with the H. pylori genotype. This study included 504 patients from two public hospitals in Brazil's north and northeast regions. The samples were classified into active and inactive gastritis, metaplasia, and GC. Polymorphisms in the DNA repair genes MLH1-93G > A, APE1 2197 T > G, XRCC1 28,152 G > A, MGMT 533 A > G, and XRCC3 18,067C > T were investigated by RFLP-PCR and H. pylori genotype by PCR. Statistical analyses were conducted using EPINFO 7.0., SNPSTAT, and CART software. The XRCC1 (GA) polymorphic allele stood out because it was associated with a lower risk of more severe gastric disease progression. Haplotypes of XRCC1 (GA) associated with some genotypes of MGMT, XRCC3, MLH1, and APE1 also showed protection against the progression of gastric diseases. XRCC3 (CT) showed a decreased risk of gastric disease progression in women, while a risk 1.3x to GC was observed in the MLH1 (A) polymorphic allele. The interaction between H. pylori genes and the host showed that the H. pylori cagE gene was the most important virulence factor associated with a worse clinical outcome, even overlapping with the XRCC1 polymorphism, where the MLH1 polymorphism response varied according to vacA alleles. Our results show the relevance of XRCC1 G > A for genome integrity, sex influence, and interaction between H. pylori virulence factors and XRCC1 and MLH1 genotypes for gastric lesion outcomes in Brazilian populations.

2024-12-31·Epigenetics

A dual-gene panel of two fragments of methylated IRF4 and one of ZEB2 in plasma cell-free DNA for gastric cancer detection

Article

作者: Zhao, Yanteng ; Wang, Zhilong ; Bu, Chunxiao ; Lv, Xianping

Early detection is crucial for increasing the survival rate of gastric cancer (GC). We aimed to identify a methylated cell-free DNA (cfDNA) marker panel for detecting GC. The differentially methylated CpGs (DMCs) were selected from datasets of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The selected DMCs were validated and further selected in tissue samples (40 gastric cancer and 36 healthy white blood cell samples) and in a quarter sample volume of plasma samples (37 gastric cancer, 12 benign gastric disease, and 43 healthy individuals). The marker combination selected was then evaluated in a normal sample volume of plasma samples (35 gastric cancer, 39 control diseases, and 40 healthy individuals) using real-time methylation-specific PCR (MSP). The analysis of the results compared methods based on 2^-ΔΔCt values and Ct values. In the results, 30 DMCs were selected through bioinformatics methods, and then 5 were selected for biological validation. The marker combination of two fragments of IRF4 (IRF4-1 and IRF4-2) and one of ZEB2 was selected due to its good performance. The Ct-based method was selected for its good results and practical advantages. The assay, IRF4-1 and IRF4-2 in one fluorescence channel and ZEB2 in another, obtained 74.3% sensitivity for the GC group at any stage, at 92.4% specificity. In conclusion, the panel of IRF4 and ZEB2 in plasma cfDNA demonstrates good diagnostic performance and application potential in clinical settings.

2024-08-09·Medicine

Exploring the correlation between gut microbiota and benign gastric tumors: A Mendelian randomization study

Article

作者: Liu, Jun ; Sun, Tao ; An, Zhen

Recent scientific research has verified a link between malignant tumors in the stomach and the gut microbiota. This research employed Mendelian randomization (MR) techniques to explore the association between gut microbiota and benign gastric malignancies. The data were derived from genome wide association studies-aggregated data consisting of 211 gut microbes and benign gastric lesions and analyzed by MR. Five statistical tools, including inverse variance weighting, weighted median, MR-Egger, simple mode, and weighted mode, were employed in the statistical analysis. The utilization of the leave-one-out approach served as an effective means of detecting data outliers. Furthermore, implementing Mendelian Randomization Pleiotropy RESidual Sum and Outlier (MR-PRESSO) and MR-Egger intercepts was employed to mitigate the impact of horizontal pleiotropy. The Cochran Q scores for inverse variance weighting and MR-Egger were utilized to determine the extent of heterogeneity. The findings indicate that the family Porphyromonadaceae (odds ratio [OR] = 2.185, 95% confidence interval [CI]: 1.239–3.855, P = .007), class Bacilli (OR = 1.556, 95%CI: 1.091 − 2.220, P = .015), family Lactobacillaceae (OR = 1.437, 95%CI: 1.049 − 1.969, P = .024), family Oxalobacteraceae (OR = 1.290, 95%CI: 1.035 − 1.608, P = .023) are positively associated with the occurrence of benign gastric tumors. Conversely, the family Pasteurellaceae (OR = 0.752, 95%CI: 0.566 − 0.999, P = .049) and family Peptococcaceae (OR = 0.622, 95%CI: 0.425 − 0.908, P = .014) exhibit a protective effect and significantly decrease the likelihood of benign gastric tumors. The findings of this study suggest that the probability of developing benign gastric tumors is positively associated with the presence of the family Porphyromonadaceae, class Bacilli, family Lactobacillaceae and family Oxalobacteraceae, In contrast, the presence of the family Pasteurellaceae and family Peptococcaceae is negatively associated with this risk. Therefore, regulating gut microbiota may be a potential strategy to reduce the incidence of benign gastric tumors.

项与良性胃溃疡相关的新闻（医药）

2024-09-04

·Pharmaceutical Technology

FDA approves Azurity’s Nymalize oral solution in prefilled syringe

Nymalize is indicated for use in adult patients with subarachnoid haemorrhage from ruptured intracranial berry aneurysms. Credit: Radiological imaging/Shutterstock. Azurity Pharmaceuticals’ Nymalize (nimodipine) oral solution in a 30mg/5ml prefilled ENFit syringe has received US Food and Drug Administration (FDA) approval. The ready-to-use prefilled syringe offers an additional layer of security for both patients and healthcare professionals when administering medication. The oral solution in the prefilled ENFit syringe offers an effective alternative for adult subarachnoid haemorrhage patients who are unable to swallow capsules. The adoption of ENFit connectors, which are recommended by the FDA, is said to be on the rise, with around 60% of acute care facilities in the US making the switch from traditional nasogastric tubing. Nymalize improves neurological outcomes by reducing the incidence and severity of ischemic deficits in adults with subarachnoid haemorrhage from ruptured intracranial berry aneurysms. See Also: RegenxBio touts positive data for rare disease drug RGX-121 Ocaliva approval in Europe withdrawn following data re-assessment It is suitable for patients across a range of post-ictus neurological conditions, classified from Hunt and Hess Grades I to V. The Nymalize prefilled ENFit syringes (30 mg/5 ml), along with prefilled oral syringes (30 mg/5 ml and 60 mg/10 ml) and 8 oz (237 ml) bottles will soon be available for order through pharmaceutical wholesalers. Azurity Pharmaceuticals CEO Richard Blackburn stated: “Patients are our priority, and our purpose is to bring them new formulations and delivery systems that help them benefit from established medicines. “Delivering Nymalize with ENFit syringes may offer patients and healthcare professionals a more secure, reliable drug administration through standardisation.” In September 2022, the FDA granted approval for Azurity’s Konvomep (omeprazole and sodium bicarbonate for oral suspension) to treat active benign gastric ulcers .

上市批准

2023-04-11

·米内网

【关注】北京药企大爆发！首仿、首家过评同日获批

精彩内容4月10日，国家药监局官网显示，北京百奥药业的两款产品均以新分类同日获批，其中，去氨加压素注射液为首家过评，奥美拉唑碳酸氢钠胶囊（II）则是国内首仿。来源：米内网中国申报进度（MED）数据库去氨加压素注射液用于治疗中枢性尿崩症，尿崩症的诊断和鉴别诊断，治疗夜间遗尿症（六岁或以上的患者）等。米内网数据显示，2021年中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端去氨加压素注射剂销售额超过1亿元，2022年上半年同比增长近8%。在此之前，去氨加压素注射液有南京星银药业、海南中和药业等企业拥有生产批文，但并无企业过评。日前，北京百奥药业以仿制4类报产获批，视同过评，成为该产品首家过评企业。来源：米内网中国申报进度（MED）数据库奥美拉唑碳酸氢钠胶囊(Ⅱ)用于活动性十二指肠溃疡的短期治疗、活动性良性胃溃疡的短期治疗（4-8周）、胃食管反流病（GERD）、糜烂性食管炎的治疗等。2021年中国公立医疗机构终端奥美拉唑碳酸氢钠胶囊剂销售额超过2亿元，2022年上半年同比增长8.18%。目前，奥美拉唑碳酸氢钠胶囊剂已获批的产品有奥美拉唑碳酸氢钠胶囊和奥美拉唑碳酸氢钠胶囊(Ⅱ)，北京百奥药业则拿下奥美拉唑碳酸氢钠胶囊(Ⅱ)的首仿。今年以来，北京百奥药业已有4款产品获批上市，涵盖消化系统及代谢药、心脑血管系统药物等多个治疗大类。资料来源：国家药监局官网、米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准一致性评价

2023-03-01

·药闻康策

新版医保药品目录变化梳理（附详细对比明细）

《国家基本医疗保险、工伤保险和生育保险药品目录》（简称《药品目录》）是基本医疗保险和生育保险基金支付药品费用的标准。2022版《药品目录》于2023年3月1日正式执行，我们对比了2022版与2021版《药品目录》，现整理如下，供大家参考。2022版概况2022版国家医保药品目录共计2967种。其中西药1293个（甲类395个），中成药1311个（含民族药93个，甲类246个），协议期内谈判药品363个（西药293个、中成药70个，全部为乙类）。对比2021版目录种类变化见下表。西药目录变化除品种数量增减外，新版目录最大的变化是109种药品取消了限制条件（备注），9种药品限制条件发生变化。同时，凡例中对“肠内外营养制剂”的限制条件取消了“重症”二字，修改为“需经营养风险筛查，明确具有营养风险，且不能经饮食或使用‘肠内营养剂’补充足够营养的住院患者方予支付”。另外，“氨基葡萄糖口服常释剂型”取消了“限工伤保险支付”的限制条件,因而2022版药品目录中工伤保险限制支付品种由6种调整为了5种。小编提醒：2022版药品目录虽然取消了部分限制条件，但在实际工作中仍建议参照说明书进行支付管理。谈判药目录变化新增谈判药108种，原有谈判药中有20种直接纳入了西药目录，无谈判药品移除。谈判药新增108种属性药品名称备注增减对比乙奥美拉唑碳酸氢钠干混悬剂 (I)限活动性十二指肠溃疡或胃食管反流病。新增乙奥美拉唑碳酸氢钠干混悬剂 (Ⅱ)限活动性良性胃溃疡。新增乙替戈拉生片限反流性食管炎。新增乙昂丹司琼口溶膜新增乙奈妥匹坦帕洛诺司琼胶囊新增乙磷酸钠盐散新增乙德谷胰岛素利拉鲁肽注射液限血糖控制不佳的成人2型糖尿病患者。新增乙盐酸二甲双胍缓释片(Ⅲ)新增乙西格列他钠片新增乙脯氨酸恒格列净片限成人2型糖尿病患者。新增乙艾地骨化醇软胶囊限绝经后女性骨质疏松症。新增乙氯吡格雷阿司匹林片新增乙曲前列尼尔注射液限肺动脉高压(PAH，WHO分类1)。新增乙注射用甲磺酸萘莫司他新增乙注射用罗普司亭限对其他治疗(例如皮质类固醇、免疫球蛋白)治疗反应不佳的成人(≥18周岁)慢性原发免疫性血小板减少症(ITP)患者。新增乙异麦芽糖酐铁注射液限口服铁剂无效或无法口服补铁；或临床上需要快速补充铁。新增乙注射用罗特西普限β-地中海贫血成人患者。新增乙达依泊汀α注射液限接受血液透析的成人慢性肾脏病患者(CKD)的贫血。新增乙中长链脂肪乳/氨基酸(16)/葡萄糖(36%)注射液需经营养风险筛查，明确具有营养风险，且不能经饮食或“肠内营养剂”补充足够营养的住院患者方予支付。新增乙结构脂肪乳(20%)/氨基酸 (16)/葡萄糖(13%)注射液需经营养风险筛查，明确具有营养风险，且不能经饮食或“肠内营养剂”补充足够营养的住院患者方予支付。新增乙小儿多种维生素注射液(13)限与肠外营养药物配合使用时支付，单独使用不予支付。新增乙艾考糊精腹膜透析液新增乙门冬氨酸钾镁木糖醇注射液限洋地黄中毒引起的心律失常患者。新增乙拉那利尤单抗注射液限12岁及以上患者预防遗传性血管性水肿(HAE)发作。新增乙瑞加诺生注射液新增乙非奈利酮片限2型糖尿病相关的慢性肾脏病成人患者。新增乙盐酸艾司洛尔氯化钠注射液新增乙比索洛尔氨氯地平片新增乙美阿沙坦钾片新增乙非诺贝酸片新增乙阿布昔替尼片限其他系统治疗(如激素或生物制剂)应答不佳或不适宜上述治疗的难治性、中重度特应性皮炎成人患者。新增乙注射用甲苯磺酸奥马环素新增乙注射用头孢唑林钠/氯化钠注射液新增乙注射用头孢美唑钠/氯化钠注射液新增乙注射用头孢呋辛钠/氯化钠注射液新增乙注射用头孢他啶/5%葡萄糖注射液新增乙注射用头孢他啶/氯化钠注射液新增乙盐酸头孢卡品酯颗粒新增乙注射用硫酸艾沙康唑限侵袭性曲霉病或侵袭性毛霉病的成人患者。新增乙对氨基水杨酸肠溶颗粒新增乙恩替卡韦颗粒限乙型肝炎。新增乙多拉米替片限艾滋病。新增乙阿兹夫定片新增乙来特莫韦片新增乙来特莫韦注射液新增乙示踪用盐酸米托蒽醌注射液限甲状腺手术区域淋巴结或乳腺癌前哨淋巴结的示踪。新增乙优替德隆注射液限既往接受过至少一种化疗方案的复发或转移性乳腺癌患者。新增乙注射用恩美曲妥珠单抗限：1.接受了紫杉烷类联合曲妥珠单抗为基础的新辅助治疗后仍残存侵袭性病灶的HER2阳性早期乳腺癌患者的辅助治疗；2.限接受了紫杉烷类和曲妥珠单抗治疗的HER2阳性、不可切除局部晚期或转移性乳腺癌患者。新增乙注射用维布妥昔单抗限以下CD30阳性淋巴瘤成人患者：1.复发或难治性系统性间变性大细胞淋巴瘤(R/RsALCL)；2.复发或难治性经典型霍奇金淋巴瘤(R/RcHL)；3.既往接受过系统性治疗的原发性皮肤间变性大细胞淋巴瘤(pcALCL)或蕈样真菌病(MF)。新增乙洛拉替尼片限间变性淋巴瘤激酶(ALK)阳性的局部晚期或转移性非小细胞肺癌患者。新增乙布格替尼片限间变性淋巴瘤激酶(ALK)阳性的局部晚期或转移性的非小细胞肺癌(NSCLC)患者。新增乙赛沃替尼片限含铂化疗后疾病进展或不耐受标准含铂化疗的、MET外显子14跳变的局部晚期或转移性NSCLC成人患者。新增乙奥雷巴替尼片限T315I突变的慢性髓细胞白血病慢性期或加速期的成年患者。新增乙瑞派替尼片限既往接受过3种或以上激酶抑制剂(包括伊马替尼)的晚期胃肠间质瘤(GIST)成人患者。新增乙维奈克拉片限成人急性髓系白血病患者。新增乙注射用卡非佐米限复发或难治性多发性骨髓瘤成人患者，患者既往至少接受过2种治疗,包括蛋白酶体抑制剂和免疫调节剂：1.每2个疗程需提供治疗有效的证据后方可继续支付；2.由三级医院血液专科或血液专科医院医师处方。新增乙羟乙磺酸达尔西利片限既往接受内分泌治疗后出现疾病进展的激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的复发或转移性乳腺癌患者。新增乙瑞维鲁胺片限转移性激素敏感性前列腺癌(mHSPC)患者。新增乙注射用醋酸地加瑞克限需要雄激素去势治疗的前列腺癌患者。新增乙奥法妥木单抗注射液限成人复发型多发性硬化(RMS)。新增乙乌帕替尼缓释片限：1.12岁及以上患者难治性、中重度特应性皮炎的二线治疗；2.活动性银屑病关节炎成人患者的二线治疗；3.中重度活动性类风湿关节炎成人患者的二线治疗。新增乙阿普米司特片限符合接受光疗或系统性治疗指征的中度至重度斑块状银屑病的成人患者。新增乙伊奈利珠单抗注射液限抗水通道蛋白4(AQP4)抗体阳性的视神经脊髓炎谱系疾病(NMOSD)成人患者。新增乙古塞奇尤单抗注射液限适合系统性治疗的成人中重度斑块状银屑病。新增乙富马酸二甲酯肠溶胶囊限成人复发型多发性硬化(RMS)。新增乙米诺膦酸片新增乙利司扑兰口服溶液用散限2月龄及以上患者的脊髓性肌萎缩症(SMA)。新增乙普瑞巴林缓释片新增乙咪达唑仑口颊粘膜溶液新增乙盐酸曲唑酮缓释片新增乙盐酸美金刚口溶膜新增乙利鲁唑口服混悬液限肌萎缩侧索硬化(ALS)。新增乙倍氯福格吸入气雾剂限慢性阻塞性肺病。新增乙茚达格莫吸入粉雾剂(II)限未能充分控制的成年哮喘患者。新增乙茚达特罗莫米松吸入粉雾剂 (II)新增乙茚达特罗莫米松吸入粉雾剂 (III)新增乙美泊利珠单抗注射液新增乙福多司坦口服溶液新增乙环孢素滴眼液(Ⅲ)限4岁及以上儿童和青少年的严重性春季角结膜炎。新增乙复方电解质眼内冲洗液新增乙肠内营养乳剂(SP)需经营养风险筛查，明确具有营养风险，且应为不能经饮食补充足够营养的住院患者方予支付。新增乙重组结核杆菌融合蛋白(EC)新增乙吸入用氯醋甲胆碱新增乙银翘清热片新增乙清肺排毒颗粒新增乙芪蛭益肾胶囊新增乙益肾养心安神片新增乙解郁除烦胶囊新增乙七蕊胃舒胶囊新增乙玄七健骨片新增乙坤心宁颗粒新增乙注射用福沙匹坦双葡甲胺限放化疗且吞咽困难的患者。新增乙硫酸镁钠钾口服用浓溶液新增乙复合磷酸氢钾注射液新增乙复方氨基酸(15AA-II)/葡萄糖(10%)电解质注射液需经营养风险筛查，明确具有营养风险，且不能经饮食或“肠内营养剂”补充足够营养的住院患者方予支付。新增乙碳酸氢钠林格注射液新增乙氨基酸(15)腹膜透析液新增乙托伐普坦片新增乙注射用多黏菌素E甲磺酸钠新增乙泊沙康唑肠溶片限13岁和13岁以上重度免疫缺陷患者。新增乙泊沙康唑注射液限18岁和18岁以上重度免疫缺陷患者。新增乙哌柏西利胶囊限激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的局部晚期或转移性乳腺癌。新增乙枸橼酸托法替布缓释片新增乙普瑞巴林口服溶液新增乙拉考沙胺注射液新增乙奥氮平口溶膜新增乙盐酸安非他酮缓释片(II)新增乙舒更葡糖钠注射液新增西药新增26种药品名称剂型状态甲凝血酶散剂新增（剂型）乙穿龙薯蓣皂苷(薯蓣皂苷)口服常释剂型新增乙注射用替莫唑胺注射液新增（剂型）乙盐酸美金刚缓释胶囊新增（剂型）乙依达拉奉注射液注射液新增（剂型）乙丙戊酸钠II缓释控释剂型新增（剂型）乙达格列净片2021谈判药调入乙盐酸奥普力农注射液2021谈判药调入乙米拉贝隆缓释片2021谈判药调入乙西他沙星片2021谈判药调入乙富马酸贝达喹啉片2021谈判药调入乙阿昔替尼片2021谈判药调入乙甲磺酸仑伐替尼胶囊2021谈判药调入乙枸橼酸伊沙佐米胶囊2021谈判药调入乙培门冬酶注射液2021谈判药调入乙恩扎卢胺软胶囊2021谈判药调入乙特立氟胺片2021谈判药调入乙注射用英夫利西单抗2021谈判药调入乙乙磺酸尼达尼布软胶囊2021谈判药调入乙盐酸鲁拉西酮片2021谈判药调入乙布南色林片2021谈判药调入乙依达拉奉氯化钠注射液2021谈判药调入乙盐酸左沙丁胺醇雾化吸入溶液2021谈判药调入乙他氟前列素滴眼液2021谈判药调入乙钆特醇注射液2021谈判药调入乙钆布醇注射液2021谈判药调入限制条件方面，24种药品发生了备注变更：一是增加了部分药品的适应症，例如：信迪利单抗注射液、替雷利珠单抗注射液等药品；二是取消了甲磺酸多拉司琼注射液、注射用尖吻蝮蛇血凝酶、丹参酮ⅡA磺酸钠注射液、拉米夫定多替拉韦片的备注限制。中成药目录变化种类无新增，莲必治注射液被移除目录。限制条件方面，16种药品存在改变，其中10种取消限制条件，6种限制条件发生改变。如清开灵注射液、丹参注射液等药品限制条件发生改变；取消参松养心胶囊、西黄丸(胶囊)、稳心片(胶囊、颗粒)等药品的备注限制。中药饮片部分变化无调整变化。（来源：易慧保Online)有需要《2022版国家医保药品目录对比》完整 Excel 电子表格，请扫描下方二维码添加客服微信咨询，申请加入药闻康策高端会员群获取。药闻康策新媒体矩阵微信公众号点击下方一键关注【免责声明】1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、点赞、点在看